US FDA Green-Lights Medtronic's CoreValve Evolut For Intermediate Risk

The approval, based on the results of the SURTAVI trial, comes a few months ahead of analysts' expectations and is welcome news for Medtronic in its effort to keep pace with TAVR leader Edwards in the US market.

Core Valve In Situ
CoreValve System in action. • Source: Medtronic PLC

US FDA approved Medtronic PLC's CoreValve Evolut transcatheter aortic to treat patients at intermediate risk for open-heart surgery just four months after the company filed the pre-market approval supplement for the expanded indication, the company announced July 10.

The CoreValve Evolut platform includes CoreValve, CoreValve Evolut R and the CoreValve Evolut PRO transcatheter valves. FDA approved CoreValve Evolut...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Approvals

More from Policy & Regulation